Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 5 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar marsuculix (< 20) Submitted: 1/4/2013 4:02:44 PM : Outperform Start Price: $11.42 SNTS Score: +56.00

a good medium-term play with a solid balance sheet - generates nice cash flow

Featured Broker Partners


Advertisement